Wedbush raises IMAX stock price target to $62 on box office growth

Wedbush raised its IMAX price target to $62 from $60, maintaining an Outperform rating, and lifted 2026 EBITDA margin guidance to above 50% from above 45%; IMAX reached a 50% margin two years ahead of schedule. The firm expects the company to surpass its $1.4 billion 2026 box office target, citing footprint expansion, upgrade opportunities and stronger 2027–2028 box-office expectations. Separately, IMAX reported record third-quarter 2026 revenue of $175 million, up 64% year over year, and adjusted EBITDA of $121 million; adjusted EPS was $2.21, or $1.58 excluding a $36.7 million tax benefit.

Analysis

The upgrade is best viewed as a call on operating leverage and deployment mix, not simply a stronger movie slate. If IMAX can grow through equipment sales and installations rather than joint ventures, it may capture revenue sooner and avoid some partner-dependent economics; verify the mix in filings before underwriting the margin trajectory. The countervailing effect is that theater operators fund upgrades: tighter capex budgets or weak returns on prior premium-format investments could slow installations even if audience demand holds.

The key valuation risk is duration. A 12x multiple applied to higher 2028 EBITDA estimates leaves the thesis exposed to forecast slippage well before the structural opportunity is resolved. Box-office diversification into local-language films may reduce dependence on a few Hollywood tentpoles, but it does not eliminate slate timing, title-quality, or release-window risk. Also separate recurring operating performance from reported EPS: the cited tax benefit makes headline earnings a poor run-rate anchor.

Near term, positive expectations may already be reflected in the analyst upgrade; the more useful 1–3 month test is whether management commentary and installation activity validate the higher-margin, sales-led growth path. Over 6–18 months, execution and operator spending matter more than the current quarter. The bullish case weakens if margin guidance slips below the stated 50% level, box-office performance fails to support the outlook, or sales-led deployments disappoint. No clean relative-value pair is established without comparable valuation and positioning data.

Key Decisions for Investors

• Do not chase the upgrade on the price target alone. Consider a staged long in IMAX only on weakness, conditional on the next company update confirming installation momentum and margin delivery; the cited target depends on higher 2028 estimates, not just current results.
• Track equipment sales versus joint-venture deployments, installation pipeline/conversions, and theater-operator capex. Treat a shift back toward slower partner-led growth or margin guidance below 50% as a thesis warning and reassess exposure.
• Normalize earnings for the disclosed tax benefit when modeling; do not extrapolate reported EPS as recurring cash-earning power. Check cash conversion and reported segment economics in filings before increasing the position.
• Catalyst watch: upcoming slate performance and management commentary on 2027–2028 box office, local-language content, and footprint expansion. A weak slate or delayed operator spending could reverse optimism even if long-term premium-format demand remains intact.